Malignant Endocrine Neoplasm — Trials

Malignant Endocrine Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

1,801 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 577
Recruiting: 292
Ph III recruiting: 34
Growth YoY: +0.7%
Industry share: 34%
Top sponsor: National Cancer Institute (NCI)
Termination share: 36.5%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (238)

clinicaltrialsPublishedShowing 301–350 of 486 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04247126	A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors	completed	Phase 1	105	Syros PharmaceuticalsINDUSTRY	1	Oct 27, 2023	clinicaltrials
NCT03366103	Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors	terminated	Phase 1 / Phase 2	15	National Cancer Institute (NCI)NIH	1	Oct 17, 2023	clinicaltrials